Andrea Huwiler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7954460/publications.pdf

Version: 2024-02-01

124 papers	5,243 citations	71102 41 h-index	106344 65 g-index
125 all docs	125 docs citations	125 times ranked	5568 citing authors

#	ARTICLE	IF	CITATIONS
1	N-Acylated and N-Alkylated 2-Aminobenzothiazoles Are Novel Agents That Suppress the Generation of Prostaglandin E2. Biomolecules, 2022, 12, 267.	4.0	1
2	Sphk1 and Sphk2 Differentially Regulate Erythropoietin Synthesis in Mouse Renal Interstitial Fibroblast-like Cells. International Journal of Molecular Sciences, 2022, 23, 5882.	4.1	3
3	Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis. Cellular Signalling, 2021, 79, 109881.	3.6	7
4	Î±-Ketoheterocycles Able to Inhibit the Generation of Prostaglandin E2 (PGE2) in Rat Mesangial Cells. Biomolecules, 2021, 11, 275.	4.0	1
5	Novel compounds with dual S1P receptor agonist and histamine H3 receptor antagonist activities act protective in a mouse model of multiple sclerosis. Neuropharmacology, 2021, 186, 108464.	4.1	13
6	Loss of sphingosine kinase 2 enhances Wilm's tumor suppressor gene 1 and nephrin expression in podocytes and protects from streptozotocin-induced podocytopathy and albuminuria in mice. Matrix Biology, 2021, 98, 32-48.	3.6	12
7	Recuperation of Vascular Homeostasis. Circulation Research, 2021, 129, 237-239.	4.5	6
8	S1P Stimulates Erythropoietin Production in Mouse Renal Interstitial Fibroblasts by S1P1 and S1P3 Receptor Activation and HIF-2Î± Stabilization. International Journal of Molecular Sciences, 2021, 22, 9467.	4.1	9
9	ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P1 Agonist and Functional Antagonist Potency In Vitro and In Vivo. Molecules, 2021, 26, 5134.	3.8	4
10	Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacological Research, 2020, 154, 104170.	7.1	82
11	Morpholino Analogues of Fingolimod as Novel and Selective S1P1 Ligands with In Vivo Efficacy in a Mouse Model of Experimental Antigen-Induced Encephalomyelitis. International Journal of Molecular Sciences, 2020, 21, 6463.	4.1	12
12	Ceramide Kinase Is Upregulated in Metastatic Breast Cancer Cells and Contributes to Migration and Invasion by Activation of PI 3-Kinase and Akt. International Journal of Molecular Sciences, 2020, 21, 1396.	4.1	23
13	Downregulation of S1P Lyase Improves Barrier Function in Human Cerebral Microvascular Endothelial Cells Following an Inflammatory Challenge. International Journal of Molecular Sciences, 2020, 21, 1240.	4.1	14
14	Sphingosine-1-phosphate promotes barrier-stabilizing effects in human microvascular endothelial cells via AMPK-dependent mechanisms. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 774-781.	3.8	13
15	Sphingolipid signaling in renal fibrosis. Matrix Biology, 2018, 68-69, 230-247.	3.6	44
16	The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. , 2018, 185, 34-49.		165
17	Small Peptides Able to Suppress Prostaglandin E2 Generation in Renal Mesangial Cells. Molecules, 2018, 23, 158.	3.8	7
18	Sphingosine Kinase 2 Modulates Retinal Neovascularization in the Mouse Model of Oxygen-Induced Retinopathy. , 2018, 59, 653.		14

#	Article	IF	Citations
19	Downregulation of the S1P Transporter Spinster Homology Protein 2 (Spns2) Exerts an Anti-Fibrotic and Anti-Inflammatory Effect in Human Renal Proximal Tubular Epithelial Cells. International Journal of Molecular Sciences, 2018, 19, 1498.	4.1	20
20	Renal Mesangial Cells Isolated from Sphingosine Kinase 2 Transgenic Mice Show Reduced Proliferation and are More Sensitive to Stress-Induced Apoptosis. Cellular Physiology and Biochemistry, 2018, 47, 2522-2533.	1.6	2
21	Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod. CNS Neuroscience and Therapeutics, 2018, 24, 984-986.	3.9	17
22	NOVEL OXAZOLO-OXAZOLE DERIVATIVES OF FINGOLIMOD INDUCE LYMPHOPENIA AND REDUCE SYMPTOMS OF EAE IN MICE. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR24-1.	0.0	0
23	Sphingosine Kinase-2 Deficiency Ameliorates Kidney Fibrosis by Up-Regulating Smad7 in a Mouse Model of Unilateral Ureteral Obstruction. American Journal of Pathology, 2017, 187, 2413-2429.	3.8	35
24	Biglycan- and Sphingosine Kinase-1 Signaling Crosstalk Regulates the Synthesis of Macrophage Chemoattractants. International Journal of Molecular Sciences, 2017, 18, 595.	4.1	31
25	Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis. Scientific Reports, 2016, 6, 27594.	3.3	43
26	Inhibitors of secreted phospholipase A 2 suppress the release of PGE 2 in renal mesangial cells. Bioorganic and Medicinal Chemistry, 2016, 24, 3029-3034.	3.0	11
27	Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments. Neuropharmacology, 2016, 105, 341-350.	4.1	20
28	Upregulation of the S1P3 receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE2 and EP2/EP4 activation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1840-1851.	2.4	25
29	Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells <i>in Vivo</i>. ACS Chemical Biology, 2016, 11, 409-414.	3.4	26
30	Transforming growth factor Î²2 (TGF-Î²2)-induced connective tissue growth factor (CTGF) expression requires sphingosine 1-phosphate receptor 5 (S1P5) in human mesangial cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 519-526.	2.4	10
31	Downregulation of sphingosine 1-phosphate (S1P) receptor 1 by dexamethasone inhibits S1P-induced mesangial cell migration. Biological Chemistry, 2015, 396, 803-812.	2.5	1
32	Sphingosine 1-Phosphate Produced by Sphingosine Kinase 2 Intrinsically Controls Platelet Aggregation In Vitro and In Vivo. Circulation Research, 2015, 117, 376-387.	4.5	69
33	Sphingosine kinase 2 deficiency increases proliferation and migration of renal mouse mesangial cells and fibroblasts. Biological Chemistry, 2015, 396, 813-825.	2.5	17
34	FTY720 and two novel butterfly derivatives exert a general anti-inflammatory potential by reducing immune cell adhesion to endothelial cells through activation of S1P3 and phosphoinositide 3-kinase. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1283-1292.	3.0	26
35	Subcellular distribution of FTY720 and FTY720-phosphate in immune cells â€“ another aspect of Fingolimod action relevant for therapeutic application. Biological Chemistry, 2015, 396, 795-802.	2.5	6
36	The ceramide kinase inhibitor <scp>NVP</scp>â€•231 inhibits breast and lung cancer cell proliferation by inducing <scp>M</scp> phase arrest and subsequent cell death. British Journal of Pharmacology, 2014, 171, 5829-5844.	5.4	56

#	Article	IF	Citations
37	Ceramide Kinase Contributes to Proliferation but not to Prostaglandin E₂ Formation in Renal Mesangial Cells and Fibroblasts. Cellular Physiology and Biochemistry, 2014, 34, 119-133.	1.6	28
38	Sphingosine 1-phosphate (S1P) induces COX-2 expression and PGE2 formation via S1P receptor 2 in renal mesangial cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 11-21.	2.4	36
39	Targeting the Sphingosine Kinase/Sphingosine 1â€Phosphate Pathway to Treat Chronic Inflammatory Kidney Diseases. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 44-49.	2.5	34
40	Synthesis and cellular characterization of novel isoxazolo- and thiazolohydrazinylidene-chroman-2,4-diones on cancer and non-cancer cell growth and death. Bioorganic and Medicinal Chemistry, 2014, 22, 2655-2661.	3.0	21
41	Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice. Neuropharmacology, 2014, 85, 314-327.	4.1	24
42	AMRâ€Me inhibits PI3K/Akt signaling in hormoneâ€dependent MCFâ€7 breast cancer cells and inactivates NFâ€Î°B in hormoneâ€independent MDAâ€MBâ€231 cells. Molecular Carcinogenesis, 2014, 53, 578-588.	2.7	21
43	Memo Has a Novel Role in S1P Signaling and Crucial for Vascular Development. PLoS ONE, 2014, 9, e94114.	2.5	15
44	PPARÎ³ agonists upregulate sphingosine 1-phosphate (S1P) receptor 1 expression, which in turn reduces S1P-induced [Ca2+]i increases in renal mesangial cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1634-1643.	2.4	13
45	Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues. Bioorganic and Medicinal Chemistry, 2013, 21, 874-882.	3.0	32
46	Sphingosine-1-phosphate: A Janus-faced mediator of fibrotic diseases. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 239-250.	2.4	74
47	Sphingosine 1-Phosphate in Renal Diseases. Cellular Physiology and Biochemistry, 2013, 31, 745-760.	1.6	39
48	The Ï‰3â€polyunsaturated fatty acid derivatives <scp>AVX</scp>001 and <scp>AVX</scp>002 directly inhibit cytosolic phospholipase <scp>A</scp>₂ and suppress <scp>PGE</scp>₂ formation in mesangial cells. British Journal of Pharmacology, 2012, 167, 1691-1701.	5.4	23
49	Targeting Sphingosine Kinase 1 in Carcinoma Cells Decreases Proliferation and Survival by Compromising PKC Activity and Cytokinesis. PLoS ONE, 2012, 7, e39209.	2.5	29
50	Activation of sphingosine kinase 2 is an endogenous protective mechanism in cerebral ischemia. Biochemical and Biophysical Research Communications, 2011, 413, 212-217.	2.1	73
51	A Prokaryotic S1P Lyase Degrades Extracellular S1P In Vitro and In Vivo: Implication for Treating Hyperproliferative Disorders. PLoS ONE, 2011, 6, e22436.	2.5	20
52	Loss of sphingosine kinaseâ€1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicinâ€induced DNA damage. British Journal of Pharmacology, 2011, 162, 532-543.	5.4	43
53	The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen. Molecular Immunology, 2011, 48, 1139-1148.	2.2	30
54	Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator. Biochemical Pharmacology, 2011, 81, 617-625.	4.4	3

#	Article	IF	Citations
55	Sphingosine kinase 1 is critically involved in nitric oxideâ€mediated human endothelial cell migration and tube formation. British Journal of Pharmacology, 2010, 160, 1641-1651.	5.4	21
56	SphK1 Regulates Proinflammatory Responses Associated with Endotoxin and Polymicrobial Sepsis. Science, 2010, 328, 1290-1294.	12.6	137
57	A Novel Mode of Action of the Putative Sphingosine Kinase Inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) Thiazole (SKI II): Induction of Lysosomal Sphingosine Kinase 1 Degradation. Cellular Physiology and Biochemistry, 2010, 26, 97-104.	1.6	60
58	Glucocorticoids protect renal mesangial cells from apoptosis by increasing cellular sphingosine-1-phosphate. Kidney International, 2010, 77, 870-879.	5.2	19
59	Sphingosine Kinase1 Is Pivotal for FcÎµRI-Mediated Mast Cell Signaling and Functional Responses In Vitro and In Vivo. Journal of Immunology, 2009, 183, 221-227.	0.8	30
60	Lipids as targets for novel anti-inflammatory therapies. , 2009, 124, 96-112.		61
61	Involvement of the ABC-transporter ABCC1 and the sphingosine 1-phosphate receptor subtype S1P3 in the cytoprotection of human fibroblasts by the glucocorticoid dexamethasone. Journal of Molecular Medicine, 2009, 87, 645-657.	3.9	59
62	The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochemical and Biophysical Research Communications, 2009, 389, 251-256.	2.1	138
63	Transforming growth factor-Î²2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-Î²2 by impeding CTGF expression. Kidney International, 2009, 76, 857-867.	5.2	66
64	New players on the center stage: Sphingosine 1-phosphate and its receptors as drug targets. Biochemical Pharmacology, 2008, 75, 1893-1900.	4.4	94
65	Sphingosine kinase-1 is a hypoxia-regulated gene that stimulates migration of human endothelial cells. Biochemical and Biophysical Research Communications, 2008, 368, 1020-1025.	2.1	75
66	Posttranslational Modification of the AU-Rich Element Binding Protein HuR by Protein Kinase CÎ´ Elicits Angiotensin II-Induced Stabilization and Nuclear Export of Cyclooxygenase 2 mRNA. Molecular and Cellular Biology, 2008, 28, 2608-2625.	2.3	167
67	Sphingosine kinase 1 and 2 regulate the capacity of mesangial cells to resist apoptotic stimuli in an opposing manner. Biological Chemistry, 2008, 389, 1399-1407.	2.5	50
68	Protein Kinase CÎ±-dependent Phosphorylation of the mRNA-stabilizing Factor HuR: Implications for Posttranscriptional Regulation of Cyclooxygenase-2. Molecular Biology of the Cell, 2007, 18, 2137-2148.	2.1	181
69	Sphingosylphosphorylcholine acts in an anti-inflammatory manner in renal mesangial cells by reducing interleukin-1Î²-induced prostaglandin E2 formation. Journal of Lipid Research, 2007, 48, 1985-1996.	4.2	11
70	Prolactin upregulates sphingosine kinase-1 expression and activity in the human breast cancer cell line MCF7 and triggers enhanced proliferation and migration. Endocrine-Related Cancer, 2007, 14, 325-335.	3.1	59
71	Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Critical Reviews in Oncology/Hematology, 2007, 63, 150-159.	4.4	59
72	Extracellular nucleotides induce migration of renal mesangial cells by upregulating sphingosine kinase-1 expression and activity. British Journal of Pharmacology, 2007, 150, 271-280.	5.4	38

#	Article	IF	Citations
73	FTY720 suppresses interleukinâ€•1Î²â€•induced secretory phospholipase A₂ expression in renal mesangial cells by a transcriptional mechanism. British Journal of Pharmacology, 2007, 150, 943-950.	5.4	18
74	De novo ceramide biosynthesis is associated with resveratrol-induced inhibition of ornithine decarboxylase activity. Biochemical Pharmacology, 2007, 74, 281-289.	4.4	28
75	Hypoxia and lipid signaling. Biological Chemistry, 2006, 387, 1321-1328.	2.5	7
76	Histamine increases sphingosine kinase-1 expression and activity in the human arterial endothelial cell line EA.hy 926 by a PKC-Î±-dependent mechanism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 367-376.	2.4	53
77	The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. British Journal of Pharmacology, 2006, 147, 164-174.	5.4	60
78	Antisense targeting of Mcl-1 has therapeutic potential in gastric cancer. Cancer Biology and Therapy, 2006, 5, 1355-1356.	3.4	5
79	Altering the Sphingosine-1-Phosphate/Ceramide Balance: A Promising Approach for Tumor Therapy. Current Pharmaceutical Design, 2006, 12, 4625-4635.	1.9	55
80	Nitric oxide downâ€•regulates the expression of the catalytic NADPH oxidase subunit Nox1 in rat renal mesangial cells. FASEB Journal, 2006, 20, 139-141.	0.5	58
81	Hypoxia Increases Group IIA Phospholipase A2Expression under Inflammatory Conditions in Rat Renal Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2005, 16, 2897-2905.	6.1	18
82	Nitric Oxide Induces TIMP-1 Expression by Activating the Transforming Growth Factor Î²-Smad Signaling Pathway. Journal of Biological Chemistry, 2005, 280, 39403-39416.	3.4	50
83	The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1738, 72-81.	2.4	86
84	PPARÎ± activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochemical and Biophysical Research Communications, 2005, 338, 1818-1824.	2.1	41
85	Sphingosine 1-Phosphate Cross-activates the Smad Signaling Cascade and Mimics Transforming Growth Factor-Î²-induced Cell Responses. Journal of Biological Chemistry, 2004, 279, 35255-35262.	3.4	166
86	Erythropoietin Is More than Just a Promoter of Erythropoiesis. Journal of the American Society of Nephrology: JASN, 2004, 15, 2240-2241.	6.1	14
87	Heterologous desensitization of the sphingosine-1-phosphate receptors by purinoceptor activation in renal mesangial cells. British Journal of Pharmacology, 2004, 143, 581-589.	5.4	25
88	Differential binding of ceramide to MEKK1 in glomerular endothelial and mesangial cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2004, 1636, 159-168.	2.4	23
89	Inhibition of Rho modulates cytokine-induced prostaglandin E2 formation in renal mesangial cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2004, 1636, 108-118.	2.4	22
90	Nephrin expression is increased in anti-Thy1.1-induced glomerulonephritis in rats. Biochemical and Biophysical Research Communications, 2004, 324, 247-254.	2.1	23

#	Article	IF	Citations
91	Effects of high glucose on cytokine-induced nerve growth factor (NGF) expression in rat renal mesangial cells. Biochemical Pharmacology, 2003, 65, 293-301.	4.4	13
92	Interleukin-1Î² inhibits ATP-induced protein kinase B activation in renal mesangial cells by two different mechanisms: the involvement of nitric oxide and ceramide. British Journal of Pharmacology, 2003, 138, 461-468.	5.4	5
93	Inflammatory cytokines upregulate nephrin expression in human embryonic kidney epithelial cells and podocytes. Biochemical and Biophysical Research Communications, 2003, 305, 136-142.	2.1	31
94	ATP Potentiates Interleukin-1Î²-induced MMP-9 Expression in Mesangial Cells via Recruitment of the ELAV Protein HuR. Journal of Biological Chemistry, 2003, 278, 51758-51769.	3.4	77
95	Nitric Oxide and Mechanisms of Redox Signaling. Journal of the American Society of Nephrology: JASN, 2003, 14, S237-S240.	6.1	25
96	Redox Signaling in Mesangial Cells. Nephron Experimental Nephrology, 2003, 93, e23-e26.	2.2	11
97	Nitric Oxide Signalling with a Special Focus on Lipid-Derived Mediators. Biological Chemistry, 2003, 384, 1379-89.	2.5	7
98	Dual Effect of Ceramide on Human Endothelial Cells. Circulation, 2002, 106, 2250-2256.	1.6	143
99	Nitric Oxide Induces Degradation of the Neutral Ceramidase in Rat Renal Mesangial Cells and Is Counterregulated by Protein Kinase C. Journal of Biological Chemistry, 2002, 277, 46184-46190.	3.4	53
100	Identification of the LIM kinase-1 as a ceramide-regulated gene in renal mesangial cells. Biochemical and Biophysical Research Communications, 2002, 298, 408-413.	2.1	13
101	Nitric oxide induces neutral ceramidase degradation by the ubiquitin/proteasome complex in renal mesangial cell cultures. FEBS Letters, 2002, 532, 441-444.	2.8	26
102	Interleukin-1 inhibits angiotensin II-stimulated protein kinase B pathway in renal mesangial cells via the inducible nitric oxide synthase. European Journal of Pharmacology, 2002, 442, 195-203.	3.5	8
103	Cross-talk between nitric oxide and superoxide determines ceramide formation and apoptosis in glomerular cells. Kidney International, 2002, 61, 790-796.	5.2	53
104	Changing gears in the course of glomerulonephritis by shifting superoxide to nitric oxide-dominated chemistry. Kidney International, 2002, 61, 809-815.	5.2	31
105	Extracellular ATP and UTP activate the protein kinase B/Akt cascade <i>via</i> the P2Y₂ purinoceptor in renal mesangial cells. British Journal of Pharmacology, 2002, 136, 520-529.	5.4	54
106	Superoxide Potently Induces Ceramide Formation in Glomerular Endothelial Cells. Biochemical and Biophysical Research Communications, 2001, 284, 404-410.	2.1	16
107	Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets. European Journal of Pharmacology, 2001, 429, 279-286.	3.5	53
108	Interleukin-1Î² Induces Chronic Activation and de Novo Synthesis of Neutral Ceramidase in Renal Mesangial Cells. Journal of Biological Chemistry, 2001, 276, 35382-35389.	3.4	61

#	Article	IF	Citations
109	Ceramide binds to the CaLB domain of cytosolic phospholipase A2and facilitates its membrane docking and arachidonic acid release. FASEB Journal, 2001, 15, 7-9.	0.5	128
110	Extracellular nucleotides activate the p38-stress-activated protein kinase cascade in glomerular mesangial cells. British Journal of Pharmacology, 2000, 129, 612-618.	5.4	47
111	Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1485, 63-99.	2.4	372
112	Cross-talk between secretory phospholipase A2 and cytosolic phospholipase A2 in rat renal mesangial cells. Lipids and Lipid Metabolism, 1997, 1348, 257-272.	2.6	84
113	Stimulation by extracellular ATP and UTP of the stress-activated protein kinase cascade in rat renal mesangial cells. British Journal of Pharmacology, 1997, 120, 807-812.	5.4	41
114	Nitric oxide stimulates stress-activated protein kinases in glomerular endothelial and mesangial cells. FEBS Letters, 1996, 396, 67-70.	2.8	56
115	CERAMIDE-BINDING AND ACTIVATION DEFINES PROTEIN KINASE c-Raf AS A CERAMIDE ACTIVATED PROTEIN KINASE. Biochemical Society Transactions, 1996, 24, 609S-609S.	3.4	0
116	Plateletâ€derived Growth Factor Stimulates <i>deâ€Novo</i> Synthesis of Mitogenâ€activated Protein Kinase in Renal Mesangial Cells. FEBS Journal, 1995, 227, 209-213.	0.2	13
117	Distinct Signaling Pathways Mediate Phorbol-Ester-Induced and Cytokine-Induced Inhibition of Erythropoietin Gene Expression. FEBS Journal, 1994, 226, 335-340.	0.2	37
118	Interleukinâ€1 stimulates de novo synthesis of mitogenâ€activated protein kinase in glomerular mesangial cells. FEBS Letters, 1994, 350, 135-138.	2.8	37
119	Transforming growth factor Î²2stimulates acute and chronic activation of the mitogen-activated protein kinase cascade in rat renal mesangial cells. FEBS Letters, 1994, 354, 255-258.	2.8	47
120	Stimulation by extracellular ATP and UTP of the mitogenâ€activated protein kinase cascade and proliferation of rat renal mesangial cells. British Journal of Pharmacology, 1994, 113, 1455-1463.	5.4	100
121	A role for protein kinase C-alpha in zymosan-stimulated eicosanoid synthesis in mouse peritoneal macrophages. FEBS Journal, 1993, 217, 69-75.	0.2	28
122	Protein kinase C inhibitors potentiate angiotensin II-induced phosphoinositide hydrolysis and intracellular Ca2+ mobilization in renal mesangial cells. European Journal of Pharmacology, 1993, 245, 15-21.	2.6	32
123	A role for protein kinase C-Ïµ in angiotensin II stimulation of phospholipase D in rat renal mesangial cells. FEBS Letters, 1993, 331, 267-271.	2.8	34
124	Inhibition of erythropoietin production by phorbol ester is associated with down-regulation of protein kinase C-Î± isoenzyme in hepatoma cells. Biochemical and Biophysical Research Communications, 1991, 179, 1441-1448.	2.1	27